Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Experimental & Clinical Cancer Research
Published in: Journal of Experimental & Clinical Cancer Research 1/2020

Open Access 01-12-2020 | Review

Histone methyltransferase and drug resistance in cancers

Authors: Cheng Yang, Jiayu Zhang, Yukui Ma, Chunfu Wu, Wei Cui, Lihui Wang

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2020

Login to get access

Abstract

A number of novel anticancer drugs have been developed in recent years. However, the mortality of cancer patients remains high because of the emergence of drug resistance. It was reported that drug resistance might involved in changes in gene expression without changing genotypes, which is similar to epigenetic modification. Some studies indicated that targeting histone methyltransferase can reverse drug resistance. Hence, the use of histone methyltransferase inhibitors or histone demethylase inhibitors opens new therapeutic approaches for cancer treatment. While the relationship between histone methyltransferase and tumor resistance has been determined, there is a lack of updated review on the association between them. In this review, we summarized the mechanisms of histone methyltransferases in cancer drug resistance and the therapeutic strategies of targeting histone methyltransferase to reverse drug resistance.
Literature
1.
Stergachis AB, Neph S, Reynolds A, Humbert R, Miller B, Paige SL, et al. Developmental fate and cellular maturity encoded in human regulatory DNA landscapes. Cell. 2013;154(4):888–903.PubMedPubMedCentral
2.
Dupont C, Armant DR, Brenner CA. Epigenetics: definition, mechanisms and clinical perspective. Semin Reprod Med. 2009;27(5):351–7.PubMedPubMedCentral
3.
Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell. 2012;150(1):12–27.PubMed
4.
Kouzarides T. Chromatin modifications and their function. Cell. 2007;128(4):693–705.PubMed
5.
Lund AH, van Lohuizen M. Epigenetics and cancer. Genes Dev. 2004;18(19):2315–35.PubMed
6.
Sermer D, Pasqualucci L, Wendel HG, Melnick A, Younes A. Emerging epigenetic-modulating therapies in lymphoma. Nat Rev Clin Oncol. 2019;16(8):494–507.PubMedPubMedCentral
7.
Graca I, Pereira-Silva E, Henrique R, Packham G, Crabb SJ, Jeronimo C. Epigenetic modulators as therapeutic targets in prostate cancer. Clin Epigenetics. 2016;8:98.PubMedPubMedCentral
8.
Tsai CT, So CW. Epigenetic therapies by targeting aberrant histone methylome in AML: molecular mechanisms, current preclinical and clinical development. Oncogene. 2017;36(13):1753–9.PubMed
9.
10.
Huo H, Magro PG, Pietsch EC, Patel BB, Scotto KW. Histone methyltransferase MLL1 regulates MDR1 transcription and chemoresistance. Cancer Res. 2010;70(21):8726–35.PubMedPubMedCentral
11.
Orouji E, Utikal J. Tackling malignant melanoma epigenetically: histone lysine methylation. Clin Epigenetics. 2018;10(1):145.PubMedPubMedCentral
12.
Xiao W, Chen X, Liu L, Shu Y, Zhang M, Zhong Y. Role of protein arginine methyltransferase 5 in human cancers. Biomed Pharmacother. 2019;114:108790.PubMed
13.
Zurita-Lopez CI, Sandberg T, Kelly R, Clarke SG. Human protein arginine methyltransferase 7 (PRMT7) is a type III enzyme forming omega-NG-monomethylated arginine residues. J Biol Chem. 2012;287(11):7859–70.PubMedPubMedCentral
14.
15.
Huang J, Perez-Burgos L, Placek BJ, Sengupta R, Richter M, Dorsey JA, et al. Repression of p53 activity by Smyd2-mediated methylation. Nature. 2006;444(7119):629–32.PubMed
16.
Xu J, Wang AH, Oses-Prieto J, Makhijani K, Katsuno Y, Pei M, et al. Arginine methylation initiates BMP-induced Smad signaling. Mol Cell. 2013;51(1):5–19.PubMedPubMedCentral
17.
Kwak YT, Guo J, Prajapati S, Park KJ, Surabhi RM, Miller B, et al. Methylation of SPT5 regulates its interaction with RNA polymerase II and transcriptional elongation properties. Mol Cell. 2003;11:1055–66.PubMed
18.
Singh PK. Histone methyl transferases: a class of epigenetic opportunities to counter uncontrolled cell proliferation. Eur J Med Chem. 2019;166:351–68.PubMed
19.
Pirola L, Ciesielski O, Balcerczyk A. The methylation status of the epigenome: its emerging role in the regulation of tumor angiogenesis and tumor growth, and potential for drug targeting. Cancers (Basel). 2018;10(8):268.
20.
Muntean AG, Hess JL. The pathogenesis of mixed-lineage leukemia. Annu Rev Pathol. 2012;7:283–301.PubMed
21.
Terranova R, Agherbi H, Boned A, Meresse S, Djabali M. Histone and DNA methylation defects at Hox genes in mice expressing a SET domain-truncated form of Mll. PNAS. 2006;103:6629–34.PubMedPubMedCentral
22.
Auclair Y, Richard S. The role of arginine methylation in the DNA damage response. DNA Repair (Amst). 2013;12(7):459–65.
23.
Zakrzewicz D, Zakrzewicz A, Preissner KT, Markart P, Wygrecka M. Protein arginine Methyltransferases (PRMTs): promising targets for the treatment of pulmonary disorders. Int J Mol Sci. 2012;13(10):12383–400.PubMedPubMedCentral
24.
Lian G, Li X, Zhang L, Zhang Y, Sun L, Zhang X, et al. Macrophage metabolic reprogramming aggravates aortic dissection through the HIF1alpha-ADAM17 pathway(). EBioMedicine. 2019;49:291–304.PubMedPubMedCentral
25.
Pal S, Vishwanath SN, Erdjument-Bromage H, Tempst P, Sif S. Human SWI/SNF-associated PRMT5 methylates histone H3 arginine 8 and negatively regulates expression of ST7 and NM23 tumor suppressor genes. Mol Cell Biol. 2004;24(21):9630–45.PubMedPubMedCentral
26.
Biggar KK, Li SS. Non-histone protein methylation as a regulator of cellular signalling and function. Nat Rev Mol Cell Biol. 2015;16(1):5–17.PubMed
27.
Skucha A, Ebner J, Grebien F. Roles of SETD2 in leukemia-transcription, DNA-damage, and beyond. Int J Mol Sci. 2019;20(5):1029.
28.
Morales Y, Caceres T, May K, Hevel JM. Biochemistry and regulation of the protein arginine methyltransferases (PRMTs). Arch Biochem Biophys. 2016;590:138–52.PubMed
29.
Jones BA, Varambally S, Arend RC. Histone methyltransferase EZH2: a therapeutic target for ovarian Cancer. Mol Cancer Ther. 2018;17(3):591–602.PubMedPubMedCentral
30.
Cao R, Wang L, Wang H, Xia L, Bromage HE, Tempst P, et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science. 2002;298:1039–43.PubMed
31.
Eskander RN, Ji T, Huynh B, Wardeh R, Randall LM, Hoang B. Inhibition of enhancer of zeste homolog 2 (EZH2) expression is associated with decreased tumor cell proliferation, migration, and invasion in endometrial cancer cell lines. Int J Gynecol Cancer. 2013;23(6):997–1005.PubMedPubMedCentral
32.
Serresi M, Siteur B, Hulsman D, Company C, Schmitt MJ, Lieftink C, et al. Ezh2 inhibition in Kras-driven lung cancer amplifies inflammation and associated vulnerabilities. J Exp Med. 2018;215(12):3115–35.PubMedPubMedCentral
33.
Yomtoubian S, Lee SB, Verma A, Izzo F, Markowitz G, Choi H, et al. Inhibition of EZH2 catalytic activity selectively targets a metastatic subpopulation in triple-negative breast Cancer. Cell Rep. 2020;30(3):755–70 e6.PubMed
34.
Xia H, Zhang W, Li Y, Guo N, Yu C. EZH2 silencing with RNA interference induces G2/M arrest in human lung cancer cells in vitro. Biomed Res Int. 2014;2014:348728.PubMedPubMedCentral
35.
Geng J, Li X, Zhou Z, Wu CL, Dai M, Bai X. EZH2 promotes tumor progression via regulating VEGF-A/AKT signaling in non-small cell lung cancer. Cancer Lett. 2015;359(2):275–87.PubMed
36.
Faber PW, Barnes GT, Jayalakshmi S, Jianmin C, Gusella JF, Macdonald ME. Huntingtin interacts with a family of WW domain proteins. Hum Mol Genet. 1998;7:1463–74.PubMed
37.
Edmunds JW, Mahadevan LC, Clayton AL. Dynamic histone H3 methylation during gene induction: HYPB/Setd2 mediates all H3K36 trimethylation. EMBO J. 2008;27(2):406–20.PubMed
38.
Zhu X, He F, Zeng H, Ling S, Chen A, Wang Y, et al. Identification of functional cooperative mutations of SETD2 in human acute leukemia. Nat Genet. 2014;46(3):287–93.PubMedPubMedCentral
39.
Niu N, Lu P, Yang Y, He R, Zhang L, Shi J, et al. Loss of Setd2 promotes Kras-induced acinar-to-ductal metaplasia and epithelia-mesenchymal transition during pancreatic carcinogenesis. Gut. 2020;69(4):715–26.PubMed
40.
Liu J, Hanavan PD, Kras K, Ruiz YW, Castle EP, Lake DF, et al. Loss of SETD2 induces a metabolic switch in renal cell carcinoma cell lines toward enhanced oxidative phosphorylation. J Proteome Res. 2019;18(1):331–40.PubMed
41.
Segovia C, San Jose-Eneriz E, Munera-Maravilla E, Martinez-Fernandez M, Garate L, Miranda E, et al. Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression. Nat Med. 2019;25(7):1073–81.PubMed
42.
Tu WB, Shiah YJ, Lourenco C, Mullen PJ, Dingar D, Redel C, et al. MYC interacts with the G9a histone methyltransferase to drive transcriptional repression and tumorigenesis. Cancer Cell. 2018;34(4):579–95 e8.PubMed
43.
44.
Gilan O, Lam EY, Becher I, Lugo D, Cannizzaro E, Joberty G, et al. Functional interdependence of BRD4 and DOT1L in MLL leukemia. Nat Struct Mol Biol. 2016;23(7):673–81.PubMed
45.
Wagner EJ, Carpenter PB. Understanding the language of Lys36 methylation at histone H3. Nat Rev Mol Cell Biol. 2012;13(2):115–26.PubMedPubMedCentral
46.
Hsu JH, Hubbell-Engler B, Adelmant G, Huang J, Joyce CE, Vazquez F, et al. PRMT1-mediated translation regulation is a crucial vulnerability of Cancer. Cancer Res. 2017;77(17):4613–25.PubMedPubMedCentral
47.
Dong F, Li Q, Yang C, Huo D, Wang X, Ai C, et al. PRMT2 links histone H3R8 asymmetric dimethylation to oncogenic activation and tumorigenesis of glioblastoma. Nat Commun. 2018;9(1):4552.PubMedPubMedCentral
48.
Stopa N, Krebs JE, Shechter D. The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond. Cell Mol Life Sci. 2015;72(11):2041–59.PubMedPubMedCentral
49.
He X, Zhu Y, Lin YC, Li M, Du J, Dong H, et al. PRMT1-mediated FLT3 arginine methylation promotes maintenance of FLT3-ITD(+) acute myeloid leukemia. Blood. 2019;134(6):548–60.PubMedPubMedCentral
50.
Zhu Y, He X, Lin YC, Dong H, Zhang L, Chen X, et al. Targeting PRMT1-mediated FLT3 methylation disrupts maintenance of MLL-rearranged acute lymphoblastic leukemia. Blood. 2019;134(15):1257–68.PubMedPubMedCentral
51.
Liu Z, Zhang R, Chen X, Yao P, Yan T, Liu W, et al. Identification of hub genes and small-molecule compounds related to intracerebral hemorrhage with bioinformatics analysis. PeerJ. 2019;7:e7782.PubMedPubMedCentral
52.
Avasarala S, Van Scoyk M, Karuppusamy Rathinam MK, Zerayesus S, Zhao X, Zhang W, et al. PRMT1 is a novel regulator of epithelial-Mesenchymal-transition in non-small cell lung Cancer. J Biol Chem. 2015;290(21):13479–89.PubMedPubMedCentral
53.
Ge L, Wang H, Xu X, Zhou Z, He J, Peng W, et al. PRMT5 promotes epithelial-mesenchymal transition via EGFR-beta-catenin axis in pancreatic cancer cells. J Cell Mol Med. 2020;24(2):1969–79.PubMed
54.
Glasspool RM, Teodoridis JM, Brown R. Epigenetics as a mechanism driving polygenic clinical drug resistance. Br J Cancer. 2006;94(8):1087–92.PubMedPubMedCentral
55.
Wilting RH, Dannenberg JH. Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance. Drug Resist Updat. 2012;15(1–2):21–38.PubMed
56.
Strub T, Ballotti R, Bertolotto C. The "ART" of epigenetics in melanoma: from histone "alterations, to resistance and therapies". Theranostics. 2020;10(4):1777–97.PubMedPubMedCentral
57.
Lamendola DE, Duan Z, Yusuf RZ, Seiden MV. Molecular description of evolving paclitaxel resistance in the SKOV-3 human ovarian carcinoma cell line. Cancer Res. 2003;63:2200–5.PubMed
58.
Xu Q, Liu Z, Guo L, Liu R, Li R, Chu X, et al. Hypoxia mediates runt-related transcription factor 2 expression via induction of vascular endothelial growth factor in periodontal ligament stem cells. Mol Cells. 2019;42(11):763–72.PubMedPubMedCentral
59.
Hu S, Yu L, Li Z, Shen Y, Wang J, Cai J, et al. Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo. Cancer Biol Ther. 2010;10(8):788–95.PubMed
60.
Chang S, Zhang DW, Xu L, Wan H, Hou TJ, Kong R. Exploring the molecular basis of RNA recognition by the dimeric RNA-binding protein via molecular simulation methods. RNA Biol. 2016;13(11):1133–43.PubMedPubMedCentral
61.
Baughn LB, Di Liberto M, Niesvizky R, Cho HJ, Jayabalan D, Lane J, et al. CDK2 phosphorylation of Smad2 disrupts TGF-beta transcriptional regulation in resistant primary bone marrow myeloma cells. J Immunol. 2009;182(4):1810–7.PubMed
62.
Sun Y, Ding L, Zhang H, Han J, Yang X, Yan J, et al. Potentiation of Smad-mediated transcriptional activation by the RNA-binding protein RBPMS. Nucleic Acids Res. 2006;34(21):6314–26.PubMedPubMedCentral
63.
Rastgoo N, Pourabdollah M, Abdi J, Reece D, Chang H. Dysregulation of EZH2/miR-138 axis contributes to drug resistance in multiple myeloma by downregulating RBPMS. Leukemia. 2018;32(11):2471–82.PubMed
64.
Wu Y, Zhang Z, Cenciarini ME, Proietti CJ, Amasino M, Hong T, et al. Tamoxifen resistance in breast Cancer is regulated by the EZH2-ERalpha-GREB1 transcriptional Axis. Cancer Res. 2018;78(3):671–84.PubMed
65.
Liu CW, Hua KT, Li KC, Kao HF, Hong RL, Ko JY, et al. Histone methyltransferase G9a drives chemotherapy resistance by regulating the glutamate-cysteine ligase catalytic subunit in head and neck squamous cell carcinoma. Mol Cancer Ther. 2017;16(7):1421–34.PubMed
66.
Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316(5827):1039–43.PubMed
67.
Chang YF, Lim KH, Chiang YW, Sie ZL, Chang J, Ho AS, et al. STAT3 induces G9a to exacerbate HER3 expression for the survival of epidermal growth factor receptor-tyrosine kinase inhibitors in lung cancers. BMC Cancer. 2019;19(1):959.PubMedPubMedCentral
68.
Wang L, Dong X, Ren Y, Luo J, Liu P, Su D, et al. Targeting EHMT2 reverses EGFR-TKI resistance in NSCLC by epigenetically regulating the PTEN/AKT signaling pathway. Cell Death Dis. 2018;9(2):129.PubMedPubMedCentral
69.
Mollinedo F, Gajate C. Fas/CD95 death receptor and lipid rafts: new targets for apoptosis-directed cancer therapy. Drug Resist Updat. 2006;9(1–2):51–73.PubMed
70.
Yamamoto TN, Lee PH, Vodnala SK, Gurusamy D, Kishton RJ, Yu Z, et al. T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy. J Clin Invest. 2019;129(4):1551–65.PubMedPubMedCentral
71.
Paschall AV, Yang D, Lu C, Choi J-H, Li X, Liu F, et al. H3K9 Trimethylation silences Fas expression to confer Colon carcinoma immune escape and 5-fluorouracil Chemoresistance. J Immunol. 2015;195(4):1868–82.PubMed
72.
Dong Y, Zhao X, Feng X, Zhou Y, Yan X, Zhang Y, et al. SETD2 mutations confer chemoresistance in acute myeloid leukemia partly through altered cell cycle checkpoints. Leukemia. 2019;33(11):2585–98.PubMedPubMedCentral
73.
Elgendy M, Fusco JP, Segura V, Lozano MD, Minucci S, Echeveste JI, et al. Identification of mutations associated with acquired resistance to sunitinib in renal cell cancer. Int J Cancer. 2019;145(7):1991–2001.PubMed
74.
Kim IK, McCutcheon JN, Rao G, Liu SV, Pommier Y, Skrzypski M, et al. Acquired SETD2 mutation and impaired CREB1 activation confer cisplatin resistance in metastatic non-small cell lung cancer. Oncogene. 2019;38(2):180–93.PubMed
75.
Liu D, Zhang XX, Li MC, Cao CH, Wan DY, Xi BX, et al. C/EBPbeta enhances platinum resistance of ovarian cancer cells by reprogramming H3K79 methylation. Nat Commun. 2018;9(1):1739.PubMedPubMedCentral
76.
Bourguignon LY, Wong G, Shiina M. Up-regulation of histone methyltransferase, DOT1L, by matrix Hyaluronan promotes MicroRNA-10 expression leading to tumor cell invasion and Chemoresistance in Cancer stem cells from head and neck squamous cell carcinoma. J Biol Chem. 2016;291(20):10571–85.PubMedPubMedCentral
77.
Liao HW, Hsu JM, Xia W, Wang HL, Wang YN, Chang WC, et al. PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response. J Clin Invest. 2015;125(12):4529–43.PubMedPubMedCentral
78.
Hsu DS, Hwang WL, Yuh CH, Chu CH, Ho YH, Chen PB, et al. Lymphotoxin-β interacts with methylated EGFR to mediate acquired resistance to Cetuximab in head and neck Cancer. Clin Cancer Res. 2017;23(15):4388–401.PubMed
79.
Musiani D, Giambruno R, Massignani E, Ippolito MR, Maniaci M, Jammula S, et al. PRMT1 is recruited via DNA-PK to chromatin where it sustains the senescence-associated secretory phenotype in response to Cisplatin. Cell Rep. 2020;30(4):1208–22 e9.PubMed
80.
Wang Z, Kong J, Wu Y, Zhang J, Wang T, Li N, et al. PRMT5 determines the sensitivity to chemotherapeutics by governing stemness in breast cancer. Breast Cancer Res Treat. 2018;168(2):531–42.PubMed
81.
Chiang K, Zielinska AE, Shaaban AM, Sanchez-Bailon MP, Jarrold J, Clarke TL, et al. PRMT5 is a critical regulator of breast Cancer stem cell function via histone methylation and FOXP1 expression. Cell Rep. 2017;21(12):3498–513.PubMedPubMedCentral
82.
Kim JH, Hwang J, Jung JH, Lee HJ, Lee DY, Kim SH. Molecular networks of FOXP family: dual biologic functions, interplay with other molecules and clinical implications in cancer progression. Mol Cancer. 2019;18(1):180.PubMedPubMedCentral
83.
Gabut M, Samavarchi-Tehrani P, Wang X, Slobodeniuc V, O'Hanlon D, Sung HK, et al. An alternative splicing switch regulates embryonic stem cell pluripotency and reprogramming. Cell. 2011;147(1):132–46.PubMed
84.
Holmes B, Benavides-Serrato A, Saunders JT, Landon KA, Schreck AJ, Nishimura RN, et al. The protein arginine methyltransferase PRMT5 confers therapeutic resistance to mTOR inhibition in glioblastoma. J Neuro-Oncol. 2019;145(1):11–22.
85.
Zheng BN, Ding CH, Chen SJ, Zhu K, Shao J, Feng J, et al. Targeting PRMT5 activity inhibits the malignancy of hepatocellular carcinoma by promoting the transcription of HNF4α. Theranostics. 2019;9(9):2606–17.PubMedPubMedCentral
86.
He W, Ma X, Yang X, Zhao Y, Qiu J, Hang H. A role for the arginine methylation of Rad9 in checkpoint control and cellular sensitivity to DNA damage. Nucleic Acids Res. 2011;39(11):4719–27.PubMedPubMedCentral
87.
Hsu MC, Pan MR, Chu PY, Tsai YL, Tsai CH, Shan YS, et al. Protein arginine methyltransferase 3 enhances chemoresistance in pancreatic cancer by methylating hnRNPA1 to increase ABCG2 expression. Cancers (Basel). 2018;11(1):8.
88.
Albiges L, Choueiri T, Escudier B, Galsky M, George D, Hofmann F, et al. A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer. Eur Urol. 2015;67(1):100–10.PubMed
89.
Adelaiye R, Ciamporcero E, Miles KM, Sotomayor P, Bard J, Tsompana M, et al. Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications. Mol Cancer Ther. 2015;14(2):513–22.PubMed
90.
Adelaiye-Ogala R, Budka J, Damayanti NP, Arrington J, Ferris M, Hsu CC, et al. EZH2 modifies Sunitinib resistance in renal cell carcinoma by Kinome reprogramming. Cancer Res. 2017;77(23):6651–66.PubMedPubMedCentral
91.
Galluzzi L, Vitale I, Michels J, Brenner C, Szabadkai G, Harel-Bellan A, et al. Systems biology of cisplatin resistance: past, present and future. Cell Death Dis. 2014;5:e1257.PubMedPubMedCentral
92.
Sun S, Zhao S, Yang Q, Wang W, Cai E, Wen Y, et al. Enhancer of zeste homolog 2 promotes cisplatin resistance by reducing cellular platinum accumulation. Cancer Sci. 2018;109(6):1853–64.PubMedPubMedCentral
93.
Qiu Z, Zhu W, Meng H, Tong L, Li X, Luo P, et al. CDYL promotes the chemoresistance of small cell lung cancer by regulating H3K27 trimethylation at the CDKN1C promoter. Theranostics. 2019;9(16):4717–29.PubMedPubMedCentral
94.
Zingg D, Arenas-Ramirez N, Sahin D, Rosalia RA, Antunes AT, Haeusel J, et al. The histone methyltransferase Ezh2 controls mechanisms of adaptive resistance to tumor immunotherapy. Cell Rep. 2017;20(4):854–67.PubMed
95.
Ciechomska IA, Marciniak MP, Jackl J, Kaminska B. Pre-treatment or post-treatment of human Glioma cells with BIX01294, the inhibitor of histone methyltransferase G9a, Sensitizes Cells to Temozolomide. Front Pharmacol. 2018;9:1271.PubMedPubMedCentral
96.
Candelaria M, de la Cruz-Hernandez E, Taja-Chayeb L, Perez-Cardenas E, Trejo-Becerril C, Gonzalez-Fierro A, et al. DNA methylation-independent reversion of gemcitabine resistance by hydralazine in cervical cancer cells. PLoS One. 2012;7(3):e29181.PubMedPubMedCentral
97.
Namgung Y, Kim SY, Kim I. Down-regulation of Survivin by BIX-01294 pretreatment overcomes resistance of hepatocellular carcinoma cells to TRAIL. Anticancer Res. 2019;39(7):3571–8.PubMed
98.
Li F, Mao G, Tong D, Huang J, Gu L, Yang W, et al. The histone mark H3K36me3 regulates human DNA mismatch repair through its interaction with MutSalpha. Cell. 2013;153(3):590–600.PubMedPubMedCentral
99.
Mar BG, Chu SH, Kahn JD, Krivtsov AV, Koche R, Castellano CA, et al. SETD2 alterations impair DNA damage recognition and lead to resistance to chemotherapy in leukemia. Blood. 2017;130(24):2631–41.PubMedPubMedCentral
100.
Pfister SX, Ahrabi S, Zalmas LP, Sarkar S, Aymard F, Bachrati CZ, et al. SETD2-dependent histone H3K36 trimethylation is required for homologous recombination repair and genome stability. Cell Rep. 2014;7(6):2006–18.PubMedPubMedCentral
101.
Daugaard M, Baude A, Fugger K, Povlsen LK, Beck H, Sorensen CS, et al. LEDGF (p75) promotes DNA-end resection and homologous recombination. Nat Struct Mol Biol. 2012;19(8):803–10.PubMed
102.
Qi J, Wu Q, Zhu X, Zhang S, Chen X, Chen W, et al. Propofol attenuates the adhesion of tumor and endothelial cells through inhibiting glycolysis in human umbilical vein endothelial cells. Acta Biochim Biophys Sin Shanghai. 2019;51(11):1114–22.PubMed
103.
Lu C, Paschall AV, Shi H, Savage N, Waller JL, Sabbatini ME, et al. The MLL1-H3K4me3 axis-mediated PD-L1 Expression and pancreatic cancer immune evasion. J Natl Cancer Inst. 2017;109(6):djw283.
104.
AbuHammad S, Cullinane C, Martin C, Bacolas Z, Ward T, Chen H, et al. Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma. Proc Natl Acad Sci U S A. 2019;116(36):17990–8000.PubMedPubMedCentral
105.
De La Rosa J, Urdiciain A, Zazpe I, Zelaya MV, Meléndez B, Rey JA, et al. The synergistic effect of DZ-NEP, panobinostat and temozolomide reduces clonogenicity and induces apoptosis in glioblastoma cells. Int J Oncol. 2020;56(1):283–300.
106.
Dimopoulos K, Sogaard Helbo A, Fibiger Munch-Petersen H, Sjo L, Christensen J, Sommer Kristensen L, et al. Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon-independent manner. Mol Oncol. 2018;12(2):180–95.PubMed
Metadata
Title
Histone methyltransferase and drug resistance in cancers
Authors
Cheng Yang
Jiayu Zhang
Yukui Ma
Chunfu Wu
Wei Cui
Lihui Wang
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2020
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/s13046-020-01682-z

Other articles of this Issue 1/2020

Journal of Experimental & Clinical Cancer Research 1/2020 Go to the issue

Research

Histone tail analysis reveals H3K36me2 and H4K16ac as epigenetic signatures of diffuse intrinsic pontine glioma

Review

Aspartate β-hydroxylase as a target for cancer therapy

Research

ULK1 inhibition as a targeted therapeutic strategy for FLT3-ITD-mutated acute myeloid leukemia

Research

A novel bispecific antibody targeting CD3 and prolactin receptor (PRLR) against PRLR-expression breast cancer

Research

Exosomal transfer of miR-15b-3p enhances tumorigenesis and malignant transformation through the DYNLT1/Caspase-3/Caspase-9 signaling pathway in gastric cancer

Research

CircTADA2A suppresses the progression of colorectal cancer via miR-374a-3p/KLF14 axis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits